TrialJournal of the American Society of Nephrology : JASN2017

Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.

Olivier Devuyst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.